deferiprone has been researched along with Agranulocytosis in 42 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 8.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "A 29-year-old male with transfusion-dependent β-thalassemia major (β-TM), splenectomized and on chelation therapy with deferiprone (DFP or L1) due to heart and liver hemosiderosis, presented with high fever and agranulocytosis." | 7.83 | A Case of Fatal Agranulocytosis That Developed in a Patient with β-Thalassemia Major Treated with Deferiprone. ( Apostolou, C; Klonizakis, P; Kotsiafti, A; Mainou, M; Psarras, K; Soulountsi, V; Vlachaki, E, 2016) |
| "Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC)." | 7.83 | Deferiprone-induced agranulocytosis: 20 years of clinical observations. ( Connelly, J; Galanello, R; Palmblad, J; Rozova, A; Spino, M; Tricta, F; Uetrecht, J, 2016) |
| "These data indicate that less frequent ANC monitoring and continuation of deferiprone therapy during neutropenia are not associated with prolonged neutropenia or with progression to agranulocytosis." | 7.80 | Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis. ( Abdel Rahman, Y; Al Damanhouri, G; Al Hawsawi, Z; Al-Tonbary, Y; Badr, M; Elalfy, M; Elsafy, U; Karakas, Z; Kilinc, Y; Qari, M; Salama, M; Shebl, S; Stilman, A; Toiber Temin, N; Tricta, F; Wali, YA; Yazman, D; Yesilipek, MA, 2014) |
| "Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking." | 7.76 | The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| " Deferiprone is one of a few drugs that are routinely used in medicine for the treatment of iron overload in thalassemic patients." | 7.75 | Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis. ( Abrol, P; Sen, R; Sharma, RK; Tewari, S, 2009) |
| "A 10-year-old girl with steroid-resistant Diamond-Blackfan anemia (DBA) developed agranulocytosis 9 weeks after chelation with deferiprone was initiated (45 mg/kg daily, 60% of recommended dose) in addition to her ordinary deferoxamine therapy." | 7.74 | Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. ( Henter, JI; Karlén, J, 2007) |
| "A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment." | 7.69 | Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). ( Castriota-Scanderbeg, A; Sacco, M, 1997) |
| "Deferiprone use was associated with a significant decline in mean serum ferritin level from 2532±1463 μg/L at baseline to 2176±1144 μg/L (P<0." | 6.75 | The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. ( El Alfy, M; El-Beshlawy, A; ElAlfy, MS; Lee, CL; Sari, TT; Tricta, F, 2010) |
| "Non chemotherapy drug-induced agranulocytosis is considered a potentially life-threatening idiosyncratic blood dyscrasia, thought to result from a partly elucidated immune and/or toxic damage on myelopoiesis, due to a multitude of drugs." | 6.46 | Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. ( Papadaki, HA; Pontikoglou, C, 2010) |
| "In paediatric patients with transfusion-dependent haemoglobinopathies, deferiprone was effective and safe in inducing control of iron overload during 12 months of treatment." | 5.34 | Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. ( Bejaoui, M; Bonifazi, D; Ceci, A; Christou, S; Cosmi, C; Cuccia, L; Del Vecchio, GC; Della Pasqua, O; El-Beshlawy, A; Felisi, M; Filosa, A; Hassab, H; Kattamis, A; Kreka, M; Maggio, A; Origa, R; Putti, MC; Reggiardo, G; Sherief, L; Spino, M; Telfer, P; Tempesta, B; Tricta, F; Tsang, YC; Vitrano, A; Zaka, A, 2020) |
| "Agranulocytosis developed in a 63-year-old patient with myelodysplasia 6 weeks after commencing treatment with the oral iron chelator deferiprone (L1, 1,2-dimethyl-3-hydroxypyrid-4-one, CP20) at a daily dose of 79 mg/kg." | 5.07 | Deferiprone-associated myelotoxicity. ( al-Refaie, FN; Hoffbrand, AV; Wonke, B, 1994) |
| "Therapy with either deferiprone (DFP) or deferoxamine (DFO) is inadequate in achieving negative iron balance in many patients with thalassemia." | 4.82 | Combined therapy with deferoxamine and deferiprone. ( Kattamis, A, 2005) |
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 4.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "Data from several trials have provided evidence for the efficacy of deferiprone in the treatment of iron overload in thalassemia major." | 4.79 | Orally active iron chelators in the treatment of iron overload. ( Olivieri, NF, 1996) |
| " The report by Lecornec and colleagues offers useful details on indications and the management of deferiprone, a highly efficient chelator in removing excess cardiac iron but associated with a high risk of agranulocytosis in DBA patients." | 4.12 | Diamond-Blackfan anaemia with iron overload: A serious issue. ( Fagioli, F; Quarello, P; Ramenghi, U, 2022) |
| " Here we report the case of a 9-year-old child with thalassaemia who developed frequent premature ventricular contractions after three doses of filgrastim were given for deferiprone-induced agranulocytosis." | 3.88 | Premature ventricular contractions as a side effect of filgrastim in a child with B-thalassaemia. ( Joshi, N; Nazir, HF; Wali, YA, 2018) |
| "A 29-year-old male with transfusion-dependent β-thalassemia major (β-TM), splenectomized and on chelation therapy with deferiprone (DFP or L1) due to heart and liver hemosiderosis, presented with high fever and agranulocytosis." | 3.83 | A Case of Fatal Agranulocytosis That Developed in a Patient with β-Thalassemia Major Treated with Deferiprone. ( Apostolou, C; Klonizakis, P; Kotsiafti, A; Mainou, M; Psarras, K; Soulountsi, V; Vlachaki, E, 2016) |
| "Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC)." | 3.83 | Deferiprone-induced agranulocytosis: 20 years of clinical observations. ( Connelly, J; Galanello, R; Palmblad, J; Rozova, A; Spino, M; Tricta, F; Uetrecht, J, 2016) |
| "These data indicate that less frequent ANC monitoring and continuation of deferiprone therapy during neutropenia are not associated with prolonged neutropenia or with progression to agranulocytosis." | 3.80 | Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis. ( Abdel Rahman, Y; Al Damanhouri, G; Al Hawsawi, Z; Al-Tonbary, Y; Badr, M; Elalfy, M; Elsafy, U; Karakas, Z; Kilinc, Y; Qari, M; Salama, M; Shebl, S; Stilman, A; Toiber Temin, N; Tricta, F; Wali, YA; Yazman, D; Yesilipek, MA, 2014) |
| "Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking." | 3.76 | The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| " Deferiprone is one of a few drugs that are routinely used in medicine for the treatment of iron overload in thalassemic patients." | 3.75 | Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis. ( Abrol, P; Sen, R; Sharma, RK; Tewari, S, 2009) |
| "A 10-year-old girl with steroid-resistant Diamond-Blackfan anemia (DBA) developed agranulocytosis 9 weeks after chelation with deferiprone was initiated (45 mg/kg daily, 60% of recommended dose) in addition to her ordinary deferoxamine therapy." | 3.74 | Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. ( Henter, JI; Karlén, J, 2007) |
| "We used combined therapy with desferrioxamine and deferiprone to treat 79 patients with severe iron overload (serum ferritin higher than 3000 ng/mL) who had low compliance with subcutaneous desferrioxamine." | 3.73 | Combined therapy with deferiprone and desferrioxamine in thalassemia major. ( Agus, A; Bina, P; Crobu, G; Defraia, E; Dessì, C; Galanello, R; Leoni, G; Muroni, PP; Origa, R, 2005) |
| "In previous trials, the orally active iron chelator deferiprone (L1) has been associated with sporadic agranulocytosis, milder forms of neutropenia and other side-effects." | 3.70 | Safety profile of the oral iron chelator deferiprone: a multicentre study. ( Cohen, AR; Dipalma, A; Galanello, R; Piga, A; Tricta, F; Vullo, C, 2000) |
| "Agranulocytosis was observed in a 63-year-old patient with myelodysplasia 6 weeks after commencing chelation with the oral iron chelator deferiprone (1,2-dimethyl-3-hydroxypyrid-4-one, L1) at a daily dose of 79 mg/kg." | 3.69 | The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system. ( al-Rafaie, FN; Hoffbrand, AV; Wilkes, S; Wonke, B, 1994) |
| "A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment." | 3.69 | Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). ( Castriota-Scanderbeg, A; Sacco, M, 1997) |
| "In patients with thalassemia intermedia (TI), such as beta-TI, alpha-thalassemia (mainly HbH disease and mild/moderate forms of HbE/beta-thalassemia), iron overload is an important challenge in terms of diagnosis, monitoring, and treatment." | 2.80 | Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. ( Calvaruso, G; Colletta, G; Di Maggio, R; Gerardi, C; Lai, E; Maggio, A; Pitrolo, L; Quota, A; Rigoli, LC; Sacco, M; Vitrano, A, 2015) |
| " Incidence of adverse effects was comparable to that in thalassemic patients." | 2.76 | Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. ( Cermak, J; Hochova, I; Jonasova, A; Neuwirtova, R; Siskova, M; Vondrakova, J; Walterova, L, 2011) |
| "Deferiprone use was associated with a significant decline in mean serum ferritin level from 2532±1463 μg/L at baseline to 2176±1144 μg/L (P<0." | 2.75 | The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. ( El Alfy, M; El-Beshlawy, A; ElAlfy, MS; Lee, CL; Sari, TT; Tricta, F, 2010) |
| "The rates of agranulocytosis (absolute neutrophil count [ANC] < 500 x 10(9)/L) and milder forms of neutropenia (ANC, 500-1500 x 10(9)/L) were 0." | 2.71 | Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. ( Cohen, AR; De Sanctis, V; Galanello, R; Piga, A; Tricta, F, 2003) |
| " These data show that the drug was effective in reducing serum ferritin levels and the incidence of adverse events was not greater than the frequency reported in clinical trials." | 2.70 | The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. ( Baiardi, P; Cappellini, MD; Carnelli, V; Ceci, A; De Sanctis, V; Felisi, M; Galanello, R; Maggio, A; Masera, G; Piga, A; Schettini, F; Stefàno, I; Tricta, F, 2002) |
| "The sporadic occurrence of agranulocytosis in association with deferiprone and the highly variable frequency of other possible side effects such as arthralgia have created uncertainty about the true incidence of deferiprone-related complications." | 2.69 | A multi-center safety trial of the oral iron chelator deferiprone. ( Cohen, A; Galanello, R; Piga, A; Tricta, F; Vullo, C, 1998) |
| "Deferiprone was clearly not effective in three patients (two with myelofibrosis, one with myelodysplasia)." | 2.68 | Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. ( Goudsmit, R; Kersten, MJ; Lameijer, W; Lange, R; Roozendaal, KJ; Smeets, ME; Vreugdenhil, G, 1996) |
| "Non chemotherapy drug-induced agranulocytosis is considered a potentially life-threatening idiosyncratic blood dyscrasia, thought to result from a partly elucidated immune and/or toxic damage on myelopoiesis, due to a multitude of drugs." | 2.46 | Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. ( Papadaki, HA; Pontikoglou, C, 2010) |
| "Deferiprone was poorly tolerated, with 40% of patients withdrawing from treatment, most commonly due to neutropenic sepsis, after an average of 2 years on treatment." | 1.56 | Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis. ( Banerjee, G; Cowley, P; Eleftheriou, P; Farmer, S; Hylton, B; Porter, J; Sammaraiee, Y; Werring, DJ, 2020) |
| "There is a lack of knowledge regarding the incidence of serious adverse drug reactions (ADR) to the oral iron chelator deferiprone in Chinese children with transfusion-dependent thalassaemia." | 1.43 | Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia. ( Botzenhardt, S; Ceci, A; Chan, GC; Felisi, M; Neubert, A; Rascher, W; Sing, CW; Wong, IC; Wong, LY, 2016) |
| "Deferiprone (L1) has been used in several countries for iron chelation therapy for over one decade." | 1.36 | Long-term response to deferiprone therapy in Asian Indians. ( Das, RR; Marwaha, RK; Panigrahi, I, 2010) |
| "Deferiprone (L1) was discontinued as it was suspected to be the offending agent and prompt broad-spectrum antibiotic therapy was initiated after which the patient improved." | 1.34 | Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient. ( Inati, A; Koussa, S; Sheikh-Taha, M; Taher, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.38) | 18.7374 |
| 1990's | 12 (28.57) | 18.2507 |
| 2000's | 11 (26.19) | 29.6817 |
| 2010's | 14 (33.33) | 24.3611 |
| 2020's | 4 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Lecornec, N | 1 |
| Castex, MP | 1 |
| Réguerre, Y | 1 |
| Moreau, P | 1 |
| Marie, I | 1 |
| Garçon, L | 1 |
| Da Costa, L | 1 |
| Leblanc, T | 1 |
| Quarello, P | 1 |
| Ramenghi, U | 1 |
| Fagioli, F | 1 |
| Sammaraiee, Y | 1 |
| Banerjee, G | 1 |
| Farmer, S | 1 |
| Hylton, B | 1 |
| Cowley, P | 1 |
| Eleftheriou, P | 1 |
| Porter, J | 1 |
| Werring, DJ | 1 |
| Maggio, A | 3 |
| Kattamis, A | 2 |
| Felisi, M | 3 |
| Reggiardo, G | 1 |
| El-Beshlawy, A | 2 |
| Bejaoui, M | 1 |
| Sherief, L | 1 |
| Christou, S | 1 |
| Cosmi, C | 1 |
| Della Pasqua, O | 1 |
| Del Vecchio, GC | 1 |
| Filosa, A | 1 |
| Cuccia, L | 1 |
| Hassab, H | 1 |
| Kreka, M | 1 |
| Origa, R | 2 |
| Putti, MC | 1 |
| Spino, M | 2 |
| Telfer, P | 1 |
| Tempesta, B | 1 |
| Vitrano, A | 2 |
| Tsang, YC | 1 |
| Zaka, A | 1 |
| Tricta, F | 8 |
| Bonifazi, D | 1 |
| Ceci, A | 3 |
| Mainou, M | 1 |
| Kotsiafti, A | 1 |
| Klonizakis, P | 1 |
| Soulountsi, V | 1 |
| Apostolou, C | 1 |
| Psarras, K | 1 |
| Vlachaki, E | 1 |
| Nazir, HF | 1 |
| Joshi, N | 1 |
| Wali, YA | 2 |
| Huprikar, N | 1 |
| Gossweiler, M | 1 |
| Callaghan, M | 1 |
| Bunge, P | 1 |
| Elalfy, M | 1 |
| Qari, M | 1 |
| Al Damanhouri, G | 1 |
| Al-Tonbary, Y | 1 |
| Yazman, D | 1 |
| Al Hawsawi, Z | 1 |
| Karakas, Z | 1 |
| Kilinc, Y | 1 |
| Yesilipek, MA | 1 |
| Badr, M | 1 |
| Elsafy, U | 1 |
| Salama, M | 1 |
| Abdel Rahman, Y | 1 |
| Shebl, S | 1 |
| Stilman, A | 1 |
| Toiber Temin, N | 1 |
| Calvaruso, G | 1 |
| Di Maggio, R | 1 |
| Lai, E | 1 |
| Colletta, G | 1 |
| Quota, A | 1 |
| Gerardi, C | 1 |
| Rigoli, LC | 1 |
| Sacco, M | 2 |
| Pitrolo, L | 1 |
| Botzenhardt, S | 1 |
| Sing, CW | 1 |
| Wong, IC | 1 |
| Chan, GC | 1 |
| Wong, LY | 1 |
| Rascher, W | 1 |
| Neubert, A | 1 |
| Uetrecht, J | 1 |
| Galanello, R | 7 |
| Connelly, J | 1 |
| Rozova, A | 1 |
| Palmblad, J | 1 |
| Panigrahi, I | 1 |
| Marwaha, RK | 1 |
| Das, RR | 1 |
| Tewari, S | 2 |
| Sharma, RK | 1 |
| Abrol, P | 1 |
| Sen, R | 1 |
| Pontikoglou, C | 1 |
| Papadaki, HA | 1 |
| ElAlfy, MS | 1 |
| El Alfy, M | 1 |
| Sari, TT | 1 |
| Lee, CL | 1 |
| Ricchi, P | 1 |
| Ammirabile, M | 1 |
| Costantini, S | 1 |
| Cinque, P | 1 |
| Lanza, AG | 1 |
| Spasiano, A | 1 |
| Di Matola, T | 1 |
| Di Costanzo, G | 1 |
| Pagano, L | 1 |
| Prossomariti, L | 1 |
| Cermak, J | 1 |
| Jonasova, A | 1 |
| Vondrakova, J | 1 |
| Walterova, L | 1 |
| Hochova, I | 1 |
| Siskova, M | 1 |
| Neuwirtova, R | 1 |
| Masera, N | 1 |
| Tavecchia, L | 1 |
| Longoni, DV | 1 |
| Maglia, O | 1 |
| Biondi, A | 1 |
| Masera, G | 2 |
| Shuchman, M | 1 |
| Cohen, AR | 2 |
| Piga, A | 5 |
| De Sanctis, V | 2 |
| Bina, P | 1 |
| Agus, A | 2 |
| Crobu, G | 1 |
| Defraia, E | 1 |
| Dessì, C | 2 |
| Leoni, G | 1 |
| Muroni, PP | 1 |
| Roggero, S | 1 |
| Vinciguerra, T | 1 |
| Sacchetti, L | 1 |
| Gallo, V | 1 |
| Longo, F | 1 |
| Henter, JI | 1 |
| Karlén, J | 1 |
| Tanner, MA | 1 |
| Smith, GC | 1 |
| Westwood, MA | 1 |
| Roughton, M | 1 |
| Assomull, R | 1 |
| Nair, SV | 1 |
| Walker, JM | 1 |
| Pennell, DJ | 1 |
| Sheikh-Taha, M | 1 |
| Koussa, S | 1 |
| Inati, A | 1 |
| Taher, A | 1 |
| al-Refaie, FN | 3 |
| Hershko, C | 2 |
| Hoffbrand, AV | 7 |
| Kosaryan, M | 1 |
| Olivieri, NF | 2 |
| Tondury, P | 1 |
| Wonke, B | 5 |
| al-Rafaie, FN | 1 |
| Wilkes, S | 2 |
| Veys, PA | 2 |
| Kersten, MJ | 1 |
| Lange, R | 1 |
| Smeets, ME | 1 |
| Vreugdenhil, G | 1 |
| Roozendaal, KJ | 1 |
| Lameijer, W | 1 |
| Goudsmit, R | 1 |
| Castriota-Scanderbeg, A | 1 |
| Cohen, A | 1 |
| Vullo, C | 2 |
| Dipalma, A | 1 |
| Richardson, DR | 1 |
| Baiardi, P | 1 |
| Cappellini, MD | 1 |
| Carnelli, V | 1 |
| Schettini, F | 1 |
| Stefàno, I | 1 |
| Alter, BP | 1 |
| Bartlett, AN | 1 |
| O'Connor, NT | 1 |
| Kontoghiorghes, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies[NCT01825512] | Phase 3 | 435 participants (Actual) | Interventional | 2014-03-17 | Completed | ||
| A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia[NCT00529152] | Phase 3 | 100 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631] | Phase 2 | 19 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in cardiac iron concentration (measured using cardiac MRI T2*), assessed as difference between value at 12 months minus value at baseline. MRI T2* is a non-invasive method based on gradient echo (GRE) sequences, where T2* represents the spin-spin relaxation times, measured in milliseconds. The faster the curve decreases (ie, the smaller T2*), the greater amount of iron is in the tissue. Treatment success was assessed as follows: if baseline cardiac T2* was less than 20 ms, an increase of 10% or more after 1 year of treatment was defined as treatment success; if baseline cardiac T2* was more than 20 ms, any increase or a decrease of less than 10% after 1 year of treatment was defined as treatment success. (NCT01825512)
Timeframe: at baseline and after 12 months
| Intervention | milliseconds (ms) (Mean) |
|---|---|
| Deferiprone | 0.488 |
| Deferasirox | 1.121 |
Change in serum ferritin level, assessed as difference between value at 12 months minus value at baseline. (NCT01825512)
Timeframe: at baseline and after 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Deferiprone | -397.583 |
| Deferasirox | -398.184 |
Change in liver iron concentration (measured using liver MRI), assessed as difference between value at 12 months minus value at baseline. (NCT01825512)
Timeframe: at baseline and after 12 months
| Intervention | mg/g (Mean) |
|---|---|
| Deferiprone | -0.848 |
| Deferasirox | -2.975 |
Percentage of successfully chelated patients is assessed by serum ferritin levels (in all patients) and cardiac MRI T2* (in patients above 10 years of age able to perform an MRI scan without sedation) (NCT01825512)
Timeframe: at baseline and after 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferiprone | 69 |
| Deferasirox | 80 |
The change in serum ferritin concentration from baseline to week 24 was measured and analyzed for all participants in the study (NCT00529152)
Timeframe: Baseline and 24 weeks
| Intervention | ug/L (Mean) |
|---|---|
| Ferriprox Oral Solution | -355.5 |
Number of Adverse Events over 24 weeks (NCT00529152)
Timeframe: 24 Weeks
| Intervention | Adverse Events (Number) |
|---|---|
| Ferriprox Oral Solution | 212 |
6 reviews available for deferiprone and Agranulocytosis
| Article | Year |
|---|---|
Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.
Topics: Agranulocytosis; Deferiprone; Humans; Iron Chelating Agents; Neutropenia; Pyridones | 2010 |
Combined therapy with deferoxamine and deferiprone.
Topics: Agranulocytosis; Biological Transport; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic | 2005 |
Deferiprone: New insight.
Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St | 2005 |
Oral iron chelation.
Topics: Administration, Oral; Agranulocytosis; Clinical Trials as Topic; Deferiprone; Humans; Iron Chelating | 1996 |
Orally active iron chelators in the treatment of iron overload.
Topics: Administration, Oral; Agranulocytosis; Chelation Therapy; Clinical Trials as Topic; Deferiprone; Hum | 1996 |
The controversial role of deferiprone in the treatment of thalassemia.
Topics: Agranulocytosis; Arthralgia; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Comb | 2001 |
11 trials available for deferiprone and Agranulocytosis
| Article | Year |
|---|---|
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Topics: Administration, Oral; Adolescent; Agranulocytosis; Albania; Anemia, Sickle Cell; beta-Thalassemia; C | 2020 |
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2015 |
The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
Topics: Administration, Oral; Agranulocytosis; Anemia, Sickle Cell; beta-Thalassemia; Chemistry, Pharmaceuti | 2010 |
Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Deferiprone; Drug Therapy, Combination; Drug-Relate | 2011 |
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
Topics: Administration, Oral; Adolescent; Adult; Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Ch | 2003 |
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2007 |
Deferiprone-associated myelotoxicity.
Topics: Adult; Agranulocytosis; Deferiprone; Female; Hematopoiesis; Humans; Iron Chelating Agents; Male; Mid | 1994 |
Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one.
Topics: Administration, Oral; Adult; Agranulocytosis; beta-Thalassemia; Deferiprone; Female; Humans; Immunol | 1993 |
Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Deferiprone; Female; Ferritins; Hemosiderosis; Huma | 1996 |
A multi-center safety trial of the oral iron chelator deferiprone.
Topics: Administration, Oral; Adolescent; Adult; Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Ch | 1998 |
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients.
Topics: Adolescent; Adult; Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Blood Transfusion; Child | 2002 |
25 other studies available for deferiprone and Agranulocytosis
| Article | Year |
|---|---|
Agranulocytosis in patients with Diamond-Blackfan anaemia (DBA) treated with deferiprone for post-transfusion iron overload: A retrospective study of the French DBA cohort.
Topics: Agranulocytosis; Anemia, Diamond-Blackfan; Deferiprone; Humans; Iron Overload; Retrospective Studies | 2022 |
Diamond-Blackfan anaemia with iron overload: A serious issue.
Topics: Agranulocytosis; Anemia, Diamond-Blackfan; Chelating Agents; Deferiprone; Humans; Iron; Iron Overloa | 2022 |
Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis.
Topics: Adult; Aged; Agranulocytosis; Brain Diseases; Deferiprone; Female; Follow-Up Studies; Hemosiderosis; | 2020 |
A Case of Fatal Agranulocytosis That Developed in a Patient with β-Thalassemia Major Treated with Deferiprone.
Topics: Adult; Agranulocytosis; beta-Thalassemia; Bone Marrow Cells; Bone Marrow Examination; Chelation Ther | 2016 |
Premature ventricular contractions as a side effect of filgrastim in a child with B-thalassaemia.
Topics: Agranulocytosis; Child; Deferiprone; Electrocardiography, Ambulatory; Filgrastim; Humans; Male; Pyri | 2018 |
Agranulocytosis with deferiprone treatment of superficial siderosis.
Topics: Aged; Agranulocytosis; Deferiprone; Humans; Iron Chelating Agents; Male; Pyridones; Siderosis | 2013 |
Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
Topics: Adolescent; Adult; Agranulocytosis; Blood Transfusion; Child; Child, Preschool; Deferiprone; Female; | 2014 |
Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.
Topics: Administration, Oral; Adolescent; Adverse Drug Reaction Reporting Systems; Agranulocytosis; Blood Tr | 2016 |
Deferiprone-induced agranulocytosis: 20 years of clinical observations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Agranulocytosis; Child; Child, Preschool; Clinical Trial | 2016 |
Long-term response to deferiprone therapy in Asian Indians.
Topics: Adolescent; Adult; Agranulocytosis; Asian People; Chelation Therapy; Child; Child, Preschool; Deferi | 2010 |
Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis.
Topics: Adolescent; Agranulocytosis; Alveolar Process; beta-Thalassemia; Blood Transfusion; Deferiprone; Dia | 2009 |
The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.
Topics: Adult; Agranulocytosis; Antiviral Agents; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, | 2010 |
Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination.
Topics: Agranulocytosis; Bone Marrow Examination; Child, Preschool; Deferiprone; Female; Humans; Iron Chelat | 2011 |
FDA panel recommends approval of deferiprone.
Topics: Agranulocytosis; Deferiprone; Drug Approval; Drug Labeling; Humans; Iron Chelating Agents; Off-Label | 2011 |
Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Topics: Adolescent; Adult; Agranulocytosis; beta-Thalassemia; Cardiovascular Diseases; Child; Deferiprone; D | 2005 |
Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia.
Topics: Agranulocytosis; Anemia, Diamond-Blackfan; Blood Cell Count; Bone Marrow; Child; Contraindications; | 2007 |
Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.
Topics: Adult; Agranulocytosis; beta-Thalassemia; Blood Transfusion; Deferiprone; Female; Humans; Intracrani | 2007 |
Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators.
Topics: Adult; Agranulocytosis; Arthritis; beta-Thalassemia; Chemical and Drug Induced Liver Injury; Deferip | 1995 |
Deferiprone in iron overload.
Topics: Agranulocytosis; Clinical Trials, Phase I as Topic; Deferiprone; Humans; Iron Chelating Agents; Join | 1995 |
The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system.
Topics: Agranulocytosis; Bone Marrow; Cell Division; Cells, Cultured; Deferiprone; Deferoxamine; Humans; Mid | 1994 |
Development of oral iron chelator L1.
Topics: Agranulocytosis; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyridones; Thalassemia | 1993 |
Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone).
Topics: Adult; Agranulocytosis; Arthritis; beta-Thalassemia; Deferiprone; Female; Humans; Pyridones; Vasculi | 1997 |
Safety profile of the oral iron chelator deferiprone: a multicentre study.
Topics: Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Deferiprone; Gastrointestinal Diseases; Hum | 2000 |
Agranulocytosis and thrombocytopenia, Blackfan-Diamond anaemia, and oral chelation.
Topics: Administration, Oral; Agranulocytosis; Anemia; Deferiprone; Humans; Iron Chelating Agents; Leukocyte | 1990 |
Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial.
Topics: Adult; Agranulocytosis; Anemia, Aplastic; Deferiprone; Female; Humans; Iron Chelating Agents; Pyrido | 1989 |